NBIXNeurocrine Biosciences, Inc.

$142.40-1.9% 1Y

$142.40

$123.1052 weeks$182.85

NBIX in its own filings

NBIX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

469

Events found in the filings · across 2,179 filings · the record starts in 1996

Hard flags: 1
Hard flags
Most recent filing: Sep 28, 2026
Most recent filing · Form 8-K
Record starts: Jun 10, 1996
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 27, 2026
Late periodic reporthistorical: 1998-04-01
Material impairmenthistorical: 2008-01-14
SEC comment-letter activity19 occurrences: 2021-11-15

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 28, 2026On September 28, 2026, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 (the “Transition Date”)Director or officer change · Form 8-K
Jul 31, 2026“Closing Date”), Neurocrine Biosciences, Inc. (“Neurocrine” or the “Company”) completed the previously announced acquisition (the “Acquisition” or “Transaction”) of Soleno.Material event (exhibits only) · press release
May 28, 2026, Neurocrine Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved an amendment of the Company’s 2025 Equity Incentive Plan (the “Amended 2025 Plan”)Director or officer change · Form 8-K
May 18, 2026The information set forth in.Material agreement entered · Form 8-K
Apr 6, 2026Agreement and Plan of Merger On April 5, 2026, Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Neurocrine, Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neurocrine (“Purchaser”) …Material agreement entered · Form 8-K
Nov 24, 2025As previously disclosed, Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (the “Company”), effective June 2, 2025. In connection with this transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement, effective as of …Director or officer change · Form 8-K